Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Project Scope 

This project team will create a White Paper with recommendations for Adverse Event Collection Instructions, with a focus on Phase 2-4 clinical trials. This project will build upon a paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices.



Project LeadsEmails

Aimee

Basile (Surface Oncology)

Basile, Otsuka Pharmaceutical

Aimee.Basile@otsuka-us

abasile@surfaceoncology

.com

Mary Nilsson

(

, Eli Lilly

)Katie Warren (

Nicola Newton, PHUSE Project Assistant

)

katie@phuse Objectives & DeliverablesTimelinesAE Relatedness blogQ4 2021 White Paper 

Q4 2022


Status
colourBlue
titleCurrent Status
Q2

/3 2022
  • Presented the Investigator-determined Causality Issue during April PHUSE Webinar Wednesday
  • Working on a poster for PHUSE/ FDA CSS 2022. Title is: Proposing the Change to Collect Investigator-determined Causality to Only Serious AE's
  • 2024

    • Published recommendations in white paper 





    Objectives & DeliverablesTimelines
    Publish White PaperQ2 2024
    Draft White Paper out for review 
    027-Aug-2020
    Project MembersOrganisationAlec VardyJazz PharmaAndrea RauchBoehringer IngelheimCathy BezekAstellasElisa YoungSouthern Star ResearchJeannine HughesBoehringer IngelheimJun LiSanofiKathy TaylorUnitherKim MusgraveAmgenKit HowardCDISCLaura GoebelJanssen Research & DevelopmentMiri Kramer MediwoundPatrick HannonMMSPranab MitraIndustryRobin WhiteEli LillyTatiana RobersonUnitherWilliam PaloAbbVie